The Effect of Recombinant Human Brain Natriuretic Peptide Combined with Sacubitril and Valsartan Treatment on Heart Rate Variability and Prognosis in Patients with Coronary Heart Failure
Objective:To observe the effect of combined use of recombinant human brain natriuretic peptide and sackubactril valsartan on heart rate variability and prognosis in patients with CHD and heart failure.Method:A total of 120 patients with CHD and heart failure admitted to Shenmusi Hospital from September 2020 to September 2022 were selected as the study objects,and were divided into control group(n=60,treated with sackubactril valsartan alone)and observation group(n=60,treated with sackubactril valsartan and recombinant human brain natriuretic peptide)according to random number table method.The efficacy,heart rate variability,myocardial injury indexes,adverse cardiovascular events,readmission rate and adverse reactions were compared between the two groups.Result:The clinical treatment efficiency of the observation group was higher than that of the control group(P<0.05).Before treatment,there was no difference in heart rate variability and myocardial injury indicators between the two groups(P>0.05).After treatment,the low-frequency component(LF)and high-frequency component(HF)of the two groups increased,while LF/HF,lactate dehydrogenase(LDH),myoglobin(Mb),and N-terminal brain natriuretic peptide precursor(NT-proBNP)decreased.The observation group had higher LF and HF than the control group,while LF/HF,LDH,Myo,and NT-proBNP were lower than the control group(P<0.05).During a 3-month dynamic follow-up,the observation group had lower rates of adverse cardiovascular events and readmission compared to the control group(P<0.05).There was no difference in adverse reactions such as dizziness,drowsiness,elevated creatinine,fatigue,nausea,and muscle pain between the observation group and the control group(P>0.05).Conclusion:The addition of recombinant human brain natriuretic peptide to the treatment of sacubitril and valsartan in patients with coronary heart disease and heart failure can significantly improve heart rate variability,reduce myocardial injury,reduce adverse cardiovascular events,enhance clinical efficacy,and have no serious adverse reactions.It is worth learning and promoting.
万方数据
维普
